Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

RGT-61159

RGT-61159 Phase 1a/b

Rgenta Therapeutics · Phase 1 · Active, not recruiting · Enrollment 105

NCT06462183

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
RGT-61159 at or below RP2DR/R ACC, evaluable (n = 39)at or below RP2D (mixed doses)Single armn/rdisease control rate: 84.6%, ASCO 2026, preliminarypartial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending